Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GDD3898 topical gel for sebaceous hyperplasia
ACTRN12622000008729Phase 2Completed
- Sponsor
- InClin
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GDD3898 in Sebaceous hyperplasia (SGH) (2 arms), sponsored by InClin. Primary endpoints: Safety of GDD3898 topical gel 1.75% and Tolerability of GDD3898 topical gel 1.75%. Started Jan 2022; status: completed.
02
Drugs
GDD3898
03
Conditions
Sebaceous hyperplasia (SGH)
Beyond the preview
Go deeper on ACTRN12622000008729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000008729.